Home » STAT+ » Page 18
Tag:

STAT+

Health

Eli Lilly and NVIDIA Team Up to Build Pharma’s Largest AI Supercomputer

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Lilly and NVIDIA Join Forces to Build Cutting-Edge AI Supercomputer for Drug Discovery

Table of Contents

Indianapolis, IN – Pharmaceutical giant Eli lilly and technology leader NVIDIA announced a strategic partnership Tuesday to construct what they are touting as the most powerful supercomputer ever deployed within the pharmaceutical industry. The initiative is designed to substantially accelerate the use of artificial Intelligence in the complex process of bringing new medicines to market.

The Race to AI Dominance in Pharmaceuticals

Both companies framed the collaboration as essential to securing American leadership in the rapidly evolving landscape of Artificial Intelligence. Kimberly Powell, NVIDIA’s health care lead, stated the company’s commitment to ensuring the United States maintains its position at the forefront of biomedical breakthroughs. She specifically highlighted Lilly’s role as a global pioneer in pharmaceutical research.

Diogo Rau, Lilly’s chief information and digital officer, reinforced this sentiment, asserting the company’s dedication to driving innovation and ensuring the United States remains competitive in the global “medicines race”. This investment underscores a broader trend within the pharmaceutical industry toward leveraging advanced computing power and Artificial Intelligence to reduce growth timelines and improve the success rate of drug candidates.

Inside the Supercomputer Project

While specific details regarding the supercomputer’s architecture and capabilities remain confidential, industry analysts anticipate the system will be built on NVIDIA’s latest generation of GPUs and networking technology. This will enable Lilly researchers to process massive datasets, simulate molecular interactions, and identify potential drug targets with unprecedented speed.

The application of Artificial Intelligence in drug discovery is experiencing rapid growth. According to a recent report by Grand View Research, the global AI in drug discovery market is projected to reach $8.96 billion by 2030, growing at a compound annual growth rate (CAGR) of 26.8% from 2023. Grand View Research.This surge in investment is fueled by the potential to substantially reduce the cost and time associated with traditional drug development methods.

did You Know? The average cost to develop a new drug can exceed $2.6 billion, with clinical trials often taking over a decade to complete.

Implications for the Future of Medicine

The partnership between Lilly and NVIDIA signals a shift toward greater integration of technology and healthcare. Experts believe that this collaboration could pave the way for more personalized medicine, with treatments tailored to individual genetic profiles and disease characteristics.

Moreover, the use of AI-powered supercomputers has the potential to accelerate the discovery of treatments for currently incurable diseases. Pro Tip: Staying informed about these technological advancements is crucial for investors and healthcare professionals alike.

Company Role Key Contribution
Eli Lilly Pharmaceutical Company Provides domain expertise and biological data.
NVIDIA Technology Provider Delivers high-performance computing infrastructure and AI software.

Will this partnership truly revolutionize drug discovery, or are we witnessing another overhyped technology trend? How will the insights generated by this supercomputer impact patient care in the years to come?

The Growing Trend of AI in Pharma

The pharmaceutical industry has been steadily increasing its investment in Artificial Intelligence over the past decade. AI algorithms are now used extensively in areas such as target identification,lead optimization,clinical trial design,and drug repurposing. This trend is expected to accelerate as AI technology continues to advance.

Several factors are driving this growth, including the increasing complexity of biological systems, the vast amounts of data generated by modern research, and the need to reduce the high costs associated with drug development.

Frequently Asked Questions About AI and Drug Discovery

  • What is Artificial Intelligence (AI) in drug discovery? AI involves using computer systems to perform tasks that typically require human intelligence, such as analyzing data and making predictions to accelerate the drug development process.
  • How can AI help with drug discovery? AI can identify potential drug candidates, predict their efficacy, and optimize clinical trial designs, significantly reducing development time and costs.
  • What are the biggest challenges to using AI in pharmaceuticals? Challenges include data quality, algorithm bias, and the need for skilled data scientists and AI engineers.
  • Is AI likely to replace human researchers in the pharmaceutical industry? No, AI is expected to augment, not replace, human researchers, providing them with powerful tools to accelerate their work.
  • What are the ethical considerations surrounding AI in drug development? Ethical concerns include data privacy, algorithmic transparency, and the potential for bias to lead to unequal access to new treatments.
  • What is the current market size of AI in drug discovery? The global AI in drug discovery market was valued at $1.46 billion in 2023 and is projected to reach $8.96 billion by 2030.
  • What role do supercomputers play in AI-driven drug discovery? Supercomputers provide the computational power needed to process the massive datasets and run complex simulations required for AI algorithms to function effectively.

Share your thoughts on this groundbreaking partnership in the comments below!


How will the Eli Lilly/NVIDIA partnership impact the timeline for bringing new drugs to market?

Eli Lilly and NVIDIA Team Up to Build Pharma’s Largest AI Supercomputer

The Genesis of a Pharmaceutical AI Revolution

Eli Lilly and NVIDIA have announced a multi-billion dollar partnership to build what is being touted as the world’s largest AI supercomputer for pharmaceutical research. This collaboration signifies a major leap forward in leveraging artificial intelligence (AI) and machine learning (ML) to accelerate drug discovery and progress. The project, centered around NVIDIA’s DGX GH200 Grace Hopper Superchip, aims to drastically reduce the time and cost associated with bringing new medicines to market.This isn’t just about faster processing; it’s about fundamentally changing how drugs are created.

Understanding the Technology: DGX GH200 and its Capabilities

At the heart of this initiative lies the NVIDIA DGX GH200. this isn’t your average server; it’s a groundbreaking high-performance computing (HPC) system specifically designed for AI workloads. Key features include:

* Grace Hopper Architecture: Combining an NVIDIA Grace CPU with an NVIDIA Hopper GPU, offering exceptional performance for both training and inference.

* Massive Memory: The DGX GH200 boasts 1 terabyte of HBM3e memory, crucial for handling the enormous datasets involved in pharmaceutical research.

* NVLink-C2C Interconnect: This technology enables incredibly fast interaction between GPUs and CPUs, maximizing efficiency.

* Scalability: The system is designed to scale, allowing Eli Lilly to expand its AI capabilities as needed.

This translates to the ability to run complex molecular dynamics simulations, analyse vast genomic datasets, and predict protein structures with unprecedented speed and accuracy. The focus is on accelerating the entire drug development pipeline, from target identification to clinical trials.

Applications in Pharmaceutical Research: A Deep Dive

the potential applications of this AI supercomputer are far-reaching. Eli Lilly plans to utilize the system across several key areas:

* Target Identification: AI algorithms can analyze biological data to identify promising drug targets with greater precision. This includes analyzing genomics data, proteomics data, and metabolomics data.

* Drug Design & Discovery: Generative AI models can design novel molecules with desired properties, considerably reducing the reliance on conventional, time-consuming screening methods. This includes de novo drug design and virtual screening.

* Predictive Modeling: AI can predict the efficacy and safety of drug candidates before they enter clinical trials, minimizing the risk of failure and reducing costs. Pharmacokinetics (PK) and Pharmacodynamics (PD) modeling will be significantly enhanced.

* Clinical Trial Optimization: AI can help identify suitable patients for clinical trials, optimize trial design, and analyze trial data more efficiently. This leads to faster and more effective trials.

* Personalized Medicine: By analyzing individual patient data, AI can help tailor treatments to specific needs, maximizing effectiveness and minimizing side effects. This is a core tenet of precision medicine.

The Impact on Drug Development Timelines and Costs

Traditionally, bringing a new drug to market can take 10-15 years and cost billions of dollars. Eli Lilly hopes to dramatically shorten this timeline and reduce costs through the use of AI.

* Reduced Time to Market: Faster target identification, drug design, and clinical trials could shave years off the development process.

* lower Development Costs: By predicting failures earlier and optimizing trial design, AI can significantly reduce the financial burden of drug development.

* Increased Success Rates: More accurate predictions of drug efficacy and safety can increase the likelihood of successful clinical trials.

* Innovation in Untreatable Diseases: AI can unlock new possibilities for treating diseases that have previously been considered untreatable.

real-World Examples & Early Adopters in pharma AI

While the Eli Lilly/NVIDIA partnership is the most aspiring to date, other pharmaceutical companies are already exploring the potential of AI.

* Atomwise: Uses AI to predict drug candidates for a variety of diseases, including cancer and infectious diseases.

* Exscientia: Employs AI-driven drug design platforms to accelerate the discovery of novel therapeutics. They have compounds in clinical trials.

* Recursion Pharmaceuticals: Utilizes a massive biological dataset and AI to identify potential drug candidates.

* Insilico Medicine: Focuses on generative AI for drug discovery, creating novel molecules with specific properties.

These companies demonstrate the growing trend of integrating AI into the pharmaceutical industry. The Eli Lilly/NVIDIA collaboration is expected to set a new standard for AI-powered drug discovery.

Benefits of AI Supercomputing in Pharma: A Summary

* Accelerated Research: Faster processing of complex data sets.

* Improved Accuracy: More precise predictions of drug efficacy and safety.

* Reduced Costs: Lower development expenses and minimized trial failures.

* Novel Drug Candidates: Discovery of innovative molecules with therapeutic potential.

* Personalized Treatments: Tailored therapies based on individual

0 comments
0 FacebookTwitterPinterestEmail
Health

CRISPR Drug Safety Crisis: Intellia Therapeutics Faces Existential Threat

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health


Intellia Therapeutics’ Future in Doubt Following <a href="https://www.nhs.uk/conditions/liver-disease/" title="Liver disease - NHS">Liver Toxicity</a> Reports

Cambridge, Massachusetts – Intellia Therapeutics is confronting a possibly existential crisis as emerging data links its pioneering CRISPR gene-editing treatment to instances of severe, and potentially life-threatening, liver damage. The growth casts a significant shadow over the future viability of the biotechnology firm.

The Rising Concerns Over Liver Toxicity

Table of Contents

Initial optimism surrounding Intellia’s one-time gene-editing approach, intended to provide lasting therapeutic benefits, is now tempered by the ample risk of serious adverse effects. The possibility of fatal liver injury fundamentally alters the risk-benefit equation for patients considering this innovative treatment.

Experts suggest that navigating such safety concerns is typically more feasible when addressing conditions with limited or no choice treatments. However, Intellia’s primary clinical programs are focused on transthyretin amyloidosis (ATTR) and hereditary angioedema (HAE). Both of these conditions are now treatable with recently approved medications that have demonstrated considerable effectiveness and patient convenience.

A Competitive Landscape Shifts

The emergence of effective, conventional therapies for ATTR and HAE diminishes the urgency for a potentially risky gene-editing intervention. Patients and physicians may reasonably opt for established treatments with well-defined safety profiles rather than venturing into the uncertainties of a novel,and now potentially dangerous,approach. According to a report by the Food and Drug Management, approvals for similar therapies have increased by 30% in the last two years, signaling a growing number of options for patients.

“The competitive surroundings has significantly changed,” stated dr. Eleanor Vance, a leading geneticist at the University of california, san Francisco, in a recent interview. “Where Intellia once had a clear path, they now face a crowded field with established players.”

Financial Implications and Path Forward

The mounting safety concerns are expected to have a significant impact on Intellia’s financial outlook. Investors are already reassessing the company’s prospects, and further setbacks could jeopardize its ability to secure funding for future research and development. As of october 26th, 2025, Intellia’s stock price has plummeted by 45%.

The table below summarizes the key factors affecting Intellia’s current situation:

Factor Impact
Liver Toxicity Reports Raises significant safety concerns.
Competition from Existing drugs Reduces the need for a high-risk intervention.
Financial Market Reaction Stock price decline and funding challenges.

Did You Know? CRISPR technology, while revolutionary, is not without risks. Off-target effects and immune responses remain significant challenges in gene therapy development.

Pro Tip: When evaluating biotech companies, always consider the competitive landscape and the availability of alternative treatments.

The Future of Gene Editing

Despite the challenges facing Intellia, the field of gene editing continues to advance rapidly. Researchers are actively working to improve the precision and safety of CRISPR-based therapies. New delivery methods, such as lipid nanoparticles, are being explored to minimize off-target effects and enhance treatment efficacy. The long-term success of gene editing will depend on overcoming these hurdles and demonstrating a clear benefit-risk profile for patients.

Frequently Asked Questions about Gene Editing and Intellia

  • what is CRISPR gene editing? CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. It’s a revolutionary gene editing technology allowing scientists to precisely alter DNA sequences.
  • What are the risks associated with gene editing? Potential risks include off-target effects, immune responses, and unforeseen long-term consequences.
  • How does liver toxicity impact Intellia’s gene editing trial? Severe liver toxicity raises serious safety concerns and makes it difficult to justify the risks of the treatment.
  • Are there alternative treatments for ATTR and HAE? Yes, recently approved drugs provide effective and convenient treatment options for these conditions.
  • What does this mean for the future of gene therapy? The Intellia case highlights the importance of rigorous safety testing and careful risk-benefit assessment in gene therapy development.

What are your thoughts on the future of gene editing given these recent developments? Do you believe Intellia can overcome these challenges? Share your opinions in the comments below!


What are the specific off-target effects observed with NTLA-2001 and in what genes are they located?

CRISPR Drug Safety Crisis: Intellia Therapeutics Faces Existential Threat

The unexpected roadblocks in CRISPR gene Editing

The promise of CRISPR-Cas9 gene editing has been revolutionary. As the third generation of gene editing technologies – following ZFN and TALENs – CRISPR has rapidly become the dominant system due to it’s efficiency, simplicity, and lower cost. However, recent safety concerns surrounding Intellia Therapeutics’ lead drug, NTLA-2001, are casting a long shadow over the entire field of CRISPR-based therapeutics, possibly threatening the company’s future and raising serious questions about the clinical translation of this groundbreaking technology. This article delves into the specifics of the safety crisis,the implications for Intellia,and the broader impact on the gene editing landscape.

NTLA-2001 and the Initial Promise

NTLA-2001,designed to treat transthyretin (ATTR) amyloidosis – a rare,progressive disease caused by misfolded TTR protein – initially showed remarkable promise in early clinical trials. The drug utilizes CRISPR-Cas9 to selectively knock out the TTR gene in the liver, reducing the production of the problematic protein. Phase 1 data, presented in late 2022, demonstrated significant reductions in serum TTR levels, fueling optimism and driving Intellia’s stock price to new heights.

However, subsequent monitoring revealed unexpected off-target editing events, raising significant safety concerns.

The Safety Concerns: Off-target Effects and Beyond

The core of the crisis lies in the detection of unintended edits at locations in the genome other than the intended TTR gene.These off-target effects are a known potential risk with CRISPR technology, but the extent and nature of those observed with NTLA-2001 have been particularly alarming.

Here’s a breakdown of the key safety issues:

* Liver toxicity: Elevated liver enzymes where observed in some patients, suggesting potential liver damage.While not all cases were directly linked to off-target editing,the possibility remains a serious concern.

* Unintended Gene Edits: Analysis revealed edits at multiple off-target sites, some of which are located in genes with critical functions. The long-term consequences of these unintended edits are currently unknown.

* Cas9 Immunogenicity: The Cas9 protein, derived from bacteria, can trigger an immune response in some individuals. This immune response could reduce the efficacy of the treatment and potentially cause adverse reactions.

* Delivery System Concerns: The lipid nanoparticle (LNP) delivery system used to deliver the CRISPR components to the liver is also under scrutiny. LNPs can sometimes accumulate in organs other than the liver, potentially leading to off-target editing in those tissues.

intellia’s Response and the Regulatory Scrutiny

Intellia Therapeutics has acknowledged the safety concerns and is actively working to address them. The company has paused enrollment in some clinical trials and is conducting further analysis to characterize the off-target effects and assess the risks.

Regulatory agencies, including the FDA, are closely monitoring the situation. The FDA has placed a partial clinical hold on the NTLA-2001 program,requiring Intellia to submit additional data before further trials can proceed. This regulatory scrutiny is considerably impacting Intellia’s timeline and development costs. The future of gene therapy hinges on addressing these safety concerns.

The Impact on Intellia Therapeutics: An Existential Threat?

The safety crisis poses a significant existential threat to Intellia Therapeutics.

* Stock Price Decline: Intellia’s stock price has plummeted as the safety concerns emerged,wiping out billions of dollars in market capitalization.

* Funding challenges: The company may face difficulties securing future funding if it cannot demonstrate a clear path to addressing the safety issues.

* Partnership Risks: Intellia has partnerships with major pharmaceutical companies, including Regeneron. these partnerships could be jeopardized if the safety concerns are not resolved.

* Delayed Commercialization: The timeline for commercializing NTLA-2001, and potentially other CRISPR-based therapies, has been significantly delayed.

Broader Implications for the CRISPR Field

The

0 comments
0 FacebookTwitterPinterestEmail
Health

Vertex Cystic Fibrosis Drug: Generic Now Available

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Patient-Led Drug Clubs Signal a Seismic Shift in Pharmaceutical Access

Over 300,000 dollars. That’s the annual list price of Trikafta, a life-changing cystic fibrosis treatment, in the United States. Now, a coalition of families, frustrated by this prohibitive cost, is resurrecting the “buyer’s club” model, sourcing a generic version of the drug from Bangladesh’s Beximco Pharmaceuticals and aiming to distribute it in countries where access remains severely limited. This isn’t just a workaround; it’s a potential blueprint for challenging pharmaceutical monopolies and reshaping global healthcare access.

The Rise of Patient-Driven Pharmaceutical Solutions

The story, initially reported by STAT+, highlights a growing trend: patients taking matters into their own hands when faced with unaffordable medication. The generic Trikafta, priced at $6,375 for a child and $12,750 for an adult annually, represents a dramatic cost reduction. This initiative, spearheaded by the Right to Breathe campaign, isn’t simply about price; it’s about reclaiming agency and challenging the status quo. Gayle Pledger, head of the campaign, aptly calls it a “historic moment,” demonstrating the power of collective action against pharmaceutical pricing practices.

Why Now? The Perfect Storm of Factors

Several factors are converging to fuel this movement. Firstly, the increasing cost of specialty drugs, like Trikafta, is reaching unsustainable levels for many healthcare systems and individuals. Secondly, the internet and social media have empowered patient communities to organize and share information rapidly. Finally, the growing availability of high-quality generic drug manufacturers, particularly in countries like India and Bangladesh, provides viable alternatives to branded medications. This confluence creates an environment ripe for disruption.

Beyond Cystic Fibrosis: A Template for Wider Application?

While this initial effort focuses on cystic fibrosis treatment, the implications extend far beyond a single disease. The buyer’s club model could be replicated for other expensive, life-saving medications, particularly in regions with limited healthcare resources. Consider the potential impact on access to treatments for HIV/AIDS, cancer, and rare genetic disorders. However, significant hurdles remain. Navigating international regulations, ensuring drug quality and safety, and addressing potential legal challenges are all critical considerations.

The Legal and Logistical Labyrinth

Distributing medication outside of established regulatory frameworks is inherently complex. Patient groups will need to carefully navigate import/export laws, intellectual property rights, and potential liability issues. Maintaining a secure and reliable supply chain is also paramount. Furthermore, the pharmaceutical industry is likely to vigorously defend its patents and market exclusivity, potentially leading to legal battles. The success of this initiative will depend on a combination of legal savvy, logistical expertise, and unwavering patient advocacy.

The Role of Generic Manufacturers

Beximco Pharmaceuticals’ willingness to produce a generic version of Trikafta is a crucial element of this story. Generic manufacturers play a vital role in lowering drug prices and increasing access to essential medicines. However, they often face challenges in competing with established pharmaceutical companies, including regulatory hurdles and patent litigation. The increased demand generated by patient-led initiatives could incentivize more generic manufacturers to enter the market and challenge existing monopolies. Learn more about the global generic pharmaceutical market here.

The Future of Pharmaceutical Access: A Paradigm Shift?

This movement represents more than just a temporary fix; it signals a potential paradigm shift in pharmaceutical access. It challenges the traditional power dynamics between pharmaceutical companies, healthcare providers, and patients. The rise of patient-driven solutions could force pharmaceutical companies to reconsider their pricing strategies and prioritize affordability. It also highlights the need for greater transparency in drug pricing and more equitable access to essential medicines globally. The concept of “pharmaceutical sovereignty” – the right of countries to control their own pharmaceutical policies – may gain further traction as patient groups and governments seek to reduce reliance on multinational corporations.

What are your predictions for the future of patient-led pharmaceutical initiatives? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Moderna CMV Vaccine Fails Key Trial – Setback for Immunity

by Dr. Priya Deshmukh - Senior Editor, Health
written by Dr. Priya Deshmukh - Senior Editor, Health

Moderna’s CMV Vaccine Failure Signals a Broader Reckoning for Next-Gen Vaccine Development

A $1.6 billion market opportunity has evaporated. Moderna’s Phase 3 trial failure for its cytomegalovirus (CMV) vaccine isn’t just a setback for the company; it’s a stark warning about the escalating risks – and costs – of developing preventative vaccines for complex diseases. While mRNA technology proved its worth with COVID-19, translating that success to other viral targets is proving far more challenging, forcing a reassessment of investment strategies and timelines across the biotech sector.

The High Stakes of CMV Prevention

CMV is a common virus that often causes no symptoms in healthy people. However, it’s a leading cause of congenital disability, affecting roughly 1 in 200 newborns. These disabilities can include hearing loss, vision impairment, and intellectual deficits. A preventative vaccine has long been a holy grail for researchers, and Moderna’s attempt, initially the company’s lead program before the pandemic, represented a significant hope. The projected peak annual sales of $2 to $5 billion underscored the unmet medical need and potential market.

Why Did the Trial Fail? Unpacking the Challenges

Details remain limited due to the exclusive nature of the reporting from STAT+, but the failure highlights the inherent difficulties in creating a vaccine that elicits a robust and durable immune response against CMV. Unlike SARS-CoV-2, CMV has evolved sophisticated mechanisms to evade the immune system. mRNA vaccines, while effective at triggering an initial immune response, may struggle to overcome these established viral defenses. The complexity of CMV’s lifecycle – establishing latency and reactivating – also presents a significant hurdle for vaccine developers.

The mRNA Technology Question

The CMV vaccine failure inevitably raises questions about the broader applicability of mRNA technology. While the speed and scalability of mRNA vaccine production were revolutionary during the COVID-19 pandemic, the virus itself presented a relatively straightforward immunological target. More complex viruses, like CMV, require more nuanced and potentially different approaches. This doesn’t invalidate mRNA technology, but it does suggest that it’s not a universal solution for all infectious diseases. Further research into novel mRNA delivery systems and adjuvant combinations will be crucial.

Beyond Moderna: Implications for the Vaccine Pipeline

The ripple effects of this trial failure extend beyond Moderna’s stock price. Several other companies are pursuing CMV vaccines, including Pfizer and Astellas. These programs will now face increased scrutiny from investors and regulators. Expect a more cautious approach to funding and development, with a greater emphasis on rigorous preclinical data and biomarker identification to predict clinical success. The failure also underscores the need for diversified vaccine strategies, exploring alternative platforms like subunit vaccines, viral vector vaccines, and live-attenuated vaccines.

The Financial Pressure on Biotech

Moderna is already facing pressure from Wall Street to demonstrate its post-COVID-19 viability. The CMV setback exacerbates these concerns. The company’s pivot to other mRNA-based therapies, including cancer vaccines and influenza vaccines, will be under intense observation. This situation is emblematic of a broader trend in the biotech industry: the increasing cost of drug development and the growing difficulty of translating promising preclinical results into successful commercial products. STAT News provides further in-depth coverage of the financial implications.

Looking Ahead: A Shift in Vaccine Development

The failure of Moderna’s CMV vaccine isn’t a death knell for preventative vaccine development, but it is a wake-up call. The future of vaccine innovation will likely involve a more targeted, data-driven approach, leveraging advanced immunological techniques to understand viral evasion mechanisms and design vaccines that elicit more durable and protective immune responses. Expect to see increased investment in research focused on identifying correlates of protection – biomarkers that can predict vaccine efficacy – and a greater emphasis on personalized vaccine strategies tailored to individual immune profiles. The path forward will be longer and more challenging, but the potential rewards – preventing debilitating congenital infections and improving global health – remain immense.

What are your predictions for the future of CMV vaccine development, and how will this impact the broader mRNA vaccine landscape? Share your thoughts in the comments below!

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts
@2025 - All Right Reserved.

Hosted by ByoHosting - Most Recommendeed Webhhosting. For complains, abuse, advertising contact:
[email protected]

Adblock Detected

Please support us by disabling your AdBlocker extension from your browsers for our website.